ISSN: 1300-0292
İndekslendiği Dizinler: SCIENCE CITATION INDEX EXPANDED
CINAHL, Index Copernicus,
Chemical Abstracts (CA),
Excerpta Medica / EMBASE
Dil: Türkçe, İngilizce
İçerik: Orijinal Araştırma, Derleme, Editöre Mektup, Olgu Sunumu, Tıp Eğitimi, Tıbbi Kitap İncelemeleri
|
|
|
Diabetes And Vanadium
Sibel TAŞ*, Melahat DİRİCAN**
* Yrd.Doç.Dr., Uludağ Üniversitesi Fen-Edebiyat Fakültesi Biyoloji Bölümü,
** Doç.Dr., Uludağ Üniversitesi Tıp Fakültesi Biyokimya AD, BURSA
Vanadium is an in vivo and in vitro insulin-mimetic agent. The administration of vanadium to the streptozotocin (STZ) diabetic rats restores hyperglycemia, improves beta cell and secretory function. In the BB diabetic rat which is a model of insulin dependent diabetes vanadyl sulfate (VS) decreases the insulin requirement by 75%. After the administration of VS for about one year no toxicity has not been observed. VS can be administrated orally or by the intraperitoneal (i.p) route . Both methods are effective when VS is administrated by either single dose or chronic doses. VS is not well absorbed; thats while a large number of organic vanadium compounds have been synthesized, tested and compared with one another. In recent years VS has been used not only in experimental studies but also orally volunteer patients with diabetes. Vanadium is deposited in bone but it is still unknown whether or not it affects bones strength or architecture. It has been shown by many studies that vanadium is a phosphatase inhibitor and vanadium can activate serine/threonine kinases distal to the insulin reseptor presumably by preventing dephosphorylation due to inhibition of phosphatases. Recent data demonstrating beneficial effects of vanadium in diabetes seem to be promising.Keywords: Vanadium, Diabetes MellitusTurkiye Klinikleri J Med Sci 2003, 23:162-165
|
|
|
|
|
